Anti-human NPFFR2 / GPR74 Recombinant Monoclonal Antibody (HM0083)
Price range: $230.00 through $720.00
Anti-human NPFFR2 recombinant monoclonal Antibody (HM0083) is a high-affinity recombinant monoclonal antibody generated by phage-display selection from a mouse-derived antibody library followed by structure-guided affinity optimization. The antibody was validated by ELISA against recombinant epitope-Fc fusion antigen and by Western blot detection of endogenous human NPFF2 protein in human cell lines.
Also known as: hNPFF2, NPFF2, NPFFR2, GPR74, NPGPR, and Neuropeptide FF receptor 2.
For research use only. Not for diagnostic or therapeutic applications.
Product Information
| Property | Description |
|---|---|
| Product Name | Anti-human NPFFR2 / GPR74 Recombinant Monoclonal Antibody |
| Antibody ID | HM0083 |
| Target Protein | Neuropeptide FF receptor 2 |
| Target Protein Short Name | hNPFF2 |
| UniProt Accession | Q9Y5X5-1, Q9Y5X5-2, Q9Y5X5-3 |
| Molecular Weight | Human isoform 1: 60.3 kDa; Human isoform 2: 48.7 kDa; Human isoform 3: 49.1 kDa |
| Antibody Type | Recombinant monoclonal antibody |
| Host Species | Mouse |
| Recombinant Format | Full-length mouse IgG1 |
| Isotype | Mouse IgG1 |
| Species Reactivity | Human |
| Tested Applications | WB |
| Recommended Dilution for WB | 1:500–1:5000 |
| Antigen | Recombinant epitope-Fc fusion protein |
| Epitope Sequence | KWDTNSSENWHPIWNVNDTKHH |
| Expression System | HEK293 cells |
| Purification | Protein G affinity chromatography |
| Conjugate | Unconjugated |
| Concentration | 0.1 mg/mL |
| Storage Buffer | 0.1 M Tris, 0.05 M Glycine, 0.07 M NaCl, 2 g/L BSA, 50% glycerol, pH 7 |
| Storage Condition | Store at -20°C. |
| Research Use | For research use only. Not for diagnostic or therapeutic applications. |
Product Background
Neuropeptide FF receptor 2 (NPFFR2), also known as GPR74, is a G protein-coupled receptor involved in neuropeptide signaling pathways associated with pain modulation, opioid signaling, energy metabolism, neuroendocrine regulation, and central nervous system function.
NPFFR2 is widely studied in neuroscience, pain biology, GPCR pharmacology, opioid receptor signaling, and metabolic regulation research. Due to its role in neuromodulatory signaling pathways, NPFFR2 has attracted interest as a potential therapeutic target in pain management and neuropsychiatric disorders.
Antibody Development
HM0083 was generated by phage-display selection using a mouse-derived antibody library. A recombinant epitope-Fc fusion protein containing the NPFFR2 epitope sequence was used as the selection antigen. Following identification of the initial antibody candidate, structure-guided affinity optimization was performed to improve binding affinity and specificity.
The optimized antibody was reconstructed as a full-length mouse IgG1 recombinant antibody and expressed in HEK293 cells.
Binding and specificity were evaluated by:
- ELISA using recombinant epitope-Fc fusion antigen
- Western blot detection of endogenous human NPFFR2 protein
Validation Data
ELISA Validation
ELISA demonstrated specific binding to recombinant epitope-Fc fusion antigen, while minimal binding was observed against Fc-only control protein.
Validation conditions:
- Fc control protein
- Epitope-Fc fusion protein
- Detection substrate: TMB
Note: ELISA validation confirms binding to epitope-Fc fusion antigen. Full-length NPFFR2 protein binding in solution has not been tested by ELISA.
Western Blot Validation – Endogenous Full-Length Protein
Western blot analysis detected endogenous human NPFF2 protein in human cell lysates under reducing conditions.
Validated samples:
- 293T cells
- HeLa cells
- HepG2 cells
Observed bands:
- Major immunoreactive bands were detected around 50–60 kDa, consistent with the expected molecular weight range of human NPFFR2 isoforms.
- Additional lower molecular weight bands may represent alternative isoforms, proteolytic fragments, partially glycosylated receptor species, or GPCR-associated processing products.
| Size | 20 ul, 100 ul |
|---|
Related products
